Beryl Drugs (524606.BO) Stock Price
Beryl Drugs Price
Over the last 12 years Beryl Drugs grew revenue by 2.1% annually, reaching 186.82 M INR. Earnings per share have grown at 4.0% per year over the last 12 years. For Beryl Drugs, the net margin of 2.3% is up versus -4.6% a few years ago.
Beryl Drugs stock price
Beryl Drugs business model & stock analysis
Frequently asked questions about Beryl Drugs
Converted at the current exchange rate, the Beryl Drugs share trades at 0.23 EUR (24.54 INR).
The revenue of Beryl Drugs is 186.82 M INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Beryl Drugs is 4.25 M INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Beryl Drugs is currently 29.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Beryl Drugs stock.
The price-to-sales ratio (P/S) of Beryl Drugs is currently 0.67. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Beryl Drugs stock.
The Eulerpool Quality Score for Beryl Drugs is 2/10.
The ISIN of Beryl Drugs is INE415H01017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Beryl Drugs is 524606.BO. The ticker symbol is used to trade Beryl Drugs shares on the stock exchange.
Beryl Drugs stock
Beryl Drugs Peer Group
Beryl Drugs FIGI
All fundamentals and in-depth analysis of Beryl Drugs
Our stock analysis for Beryl Drugs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beryl Drugs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.